Tandem Diabetes Care
TNDM
226 hedge funds and large institutions have $1.45B invested in Tandem Diabetes Care in 2023 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 80 increasing their positions, 89 reducing their positions, and 45 closing their positions.
2.99% more ownership
Funds ownership: 103.94% → 106.93% (+3%)
9% less funds holding
Funds holding: 247 → 226 (-21)
10% less repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 89
12% less call options, than puts
Call options by funds: $7.01M | Put options by funds: $7.98M
12% less capital invested
Capital invested by funds: $1.65B → $1.45B (-$205M)
42% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 45
Top Buyers
| 1 |
EC
Eminence Capital
New York
|
+$65.2M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$44.8M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$23.1M |
| 4 |
Jennison Associates
New York
|
+$22.1M |
| 5 |
CC
Chicago Capital
Chicago,
Illinois
|
+$21.7M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$43.1M |
| 2 |
Millennium Management
New York
|
-$14.9M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$13.1M |
| 4 |
Two Sigma Investments
New York
|
-$11.7M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$11.7M |
TNDM Hedge Fund Activity: Q3 2023 in Review
226 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q3 2023, worth a combined $1.45B — down 12% from $1.65B a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of TNDM and 26 opened new positions — a net loss of 19 holders — while 89 trimmed existing stakes and 80 added.
The largest buyer was Eminence Capital, adding an estimated $65.2M. The largest seller was Fidelity Investments, cutting an estimated $43.1M.
- 226 institutional investors held Tandem Diabetes Care (TNDM) as of Q3 2023, down from 247 in Q2 2023.
- Funds reported $1.45B of Tandem Diabetes Care stock for Q3 2023, down 12% quarter-over-quarter.
- 26 funds opened new Tandem Diabetes Care positions in Q3 2023 and 45 closed out, a net change of -19 holders.
- The largest Tandem Diabetes Care buyer in Q3 2023 was Eminence Capital, an estimated $65.2M added.
- The largest Tandem Diabetes Care seller in Q3 2023 was Fidelity Investments, an estimated $43.1M sold.
Based on aggregated 13F filings for Q3 2023.